GO
Loading...

Enter multiple symbols separated by commas

Stocks Sanofi SA

More

  • Midday Movers: REGN, FOSL & More Monday, 11 Feb 2013 | 2:17 PM ET

    Take a look at some of Monday midday movers:

  • Europe Stocks Mixed, Healthcare Weighs Monday, 11 Feb 2013 | 10:52 AM ET

    European shares closed lower on Monday as sharp falls in Danish pharma group Novo Nordisk outweighed rallies in rival Sanofi and Dutch retailer Ahold.

  • Early Movers: DELL, GOOG, SNY & More Monday, 11 Feb 2013 | 8:22 AM ET

    Some of the names on the move ahead of the open.

  • U.S. regulators dealt a major blow to Novo Nordisk's hopes for its new long-acting insulin Tresiba by demanding the Danish drugmaker conduct additional clinical tests to assess potential heart risks.

  • Sanofi Leads European Shares to 2013 Closing Low Thursday, 7 Feb 2013 | 9:31 AM ET

    European shares closed lower after choppy trading on Thursday, tracking falls on the U.S. equity markets.

  • Different Approach to Innovation: Sanofi CEO Thursday, 7 Feb 2013 | 4:20 AM ET
    Different Approach to Innovation: Sanofi CEO

    Christopher Viehbacher, CEO of Sanofi, pledges a different and radical approach to innovation.

  • Pfizer Profit Drops on Loss of Lipitor Exclusivity

    Pfizer's animal health subsidiary Zoetis raised $2.2 billion in its public offering on Thursday, becoming the largest IPO from a U.S. company since Facebook.

  • Denmark's Nokia Moment on $100 Billion Stock Friday, 1 Feb 2013 | 6:37 AM ET
    Copenhagen, Denmark

    Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.

  • Denmark Faces Nokia Moment on $100 Billion Stock Friday, 1 Feb 2013 | 5:28 AM ET

    Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.

  • Drug Pipelines Begin to Fill For Big Pharma Sunday, 13 Jan 2013 | 4:30 PM ET
    pills.jpg

    The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.

  • Pipeline Winners: Should You Bank on Biotech? Friday, 11 Jan 2013 | 5:09 PM ET
    prescription-drugs-2_200.jpg

    Jim Cramer’s researcher Nicole Urken reviews the potential biotech pipeline winners there were highlighted this week on Mad Money.

  • Flu Reaches Epidemic Level in U.S. Friday, 11 Jan 2013 | 4:40 PM ET
    Flu Reaches Epidemic Level in U.S.

    Widespread influenza activity has afflicted 47 states, according to the CDC. Phil Hosbach, VP of Immunization Policy, discusses whether people should be worried about dwindling supplies.

  • Sanofi CEO on Fighting the Flu Monday, 7 Jan 2013 | 4:40 PM ET
    Sanofi CEO on Fighting the Flu

    Chris Viehbacher, CEO of Sanofi, discusses growing concern over the spread of the flu this season.

  • Europe Closes Slightly Higher in Shortened Session Monday, 31 Dec 2012 | 5:24 AM ET

    European stocks were flat in early afternoon trading on Monday as fears over a lack of resolution to the U.S.' "fiscal cliff" weighed on sentiment.

  • Big Pharma Bets on Obesity Drug Binge Thursday, 27 Dec 2012 | 2:18 AM ET

    As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.

  • After-Hours Buzz: LTD, GILD & More Monday, 10 Dec 2012 | 5:10 PM ET
    market-insider-stocks-to-watch-AB-200.jpg

    Check out which companies are making headlines after the bell Monday.

  • European Stocks Close Mixed as 'Cliff' Concerns Weigh Tuesday, 4 Dec 2012 | 11:51 AM ET

    European shares ended mixed Tuesday amid "fiscal cliff" discussions in the U.S., but losses were limited as EU finance ministers met in Brussels to discuss details of a possible banking union.

  • *Amgen shares rise 1.4 percent. LOS ANGELES, Nov 6- Amgen Inc's experimental cholesterol-lowering drug, AMG145, reduced levels of ``bad'' cholesterol up to 66 percent in patients already taking statin drugs, according to results from a mid-stage trial that were presented on Tuesday.

  • UPDATE 1-Europe approves high-price gene therapy Friday, 2 Nov 2012 | 10:43 AM ET

    *European Commission clears Glybera for ultra rare disease. The formal clearance from the European Commission paves the way for a launch next summer of the treatment for an ultra rare genetic disease that will cost around 1.2 million euros per patient, a new record for pricey modern medicines.

  • Medidata jumps after announcing Sanofi contract Wednesday, 31 Oct 2012 | 4:23 PM ET

    NEW YORK-- Shares of Medidata Solutions Inc. climbed Wednesday after the research software maker said it won a contract with French drugmaker Sanofi. The companies said Sanofi will use Medidata's "cloud" technology to collect and manage clinical data for its entire research and development organization.